INNOVATIVE JOURNAL

Journal of Medical Care Research and Review

Homepage: http://mcrr.info/index.php/mcrr/index

Medical Care Research and Review
(O):2589-8949 (P): 2589-8930

Escherichia coli, Pathogenicity of Escherichia coli,Virulence factors of Escherichia coli, Secreted virulence (short review)

Rana Talib Mohsen

Department of Biotechnology, College of Science, University of Anbar, Al-Anbar

DOI: https://doi.org/10.52845/mcrr/2025/08-04-2

Abstract: The Enterobacteriaceae family of facultative anaerobic, Gram-negative, glucose-fermenting bacteria that are catalase positive and oxidase negative is associated with almost all CUAI, whereas UTIs are particularly closely related. The bacterial species E. Coli is broad and varied. Some strains of Escherichia coli can cause lung infections, pneumonia, diarrhea, and urinary tract infections (UTIs). In natural settings, both biotic and abiotic variables can affect E. Coli's ability to survive and develop. The obtainability of nutrients and water, temperature, pH, and sunlight are examples of abiotic variables. E. Coli's capacity to obtain nutrients, contest with other microbes, and create biofilms outside is one example of a biologic challenge.

Key words:Escherichia coli, Pathogenicity of Escherichia coli,Virulence factors of Escherichia coli,

GENERALCHARACTERISTICSOF*ESCHERICHIACOLI*

Escherichia coli, the biological rock star, is the current term for the rapidly proliferating bacterium he discovered during this experiment, which he dubbed bacteria coli commune (1,2) E. Coli may grow rapidly and multiply in around 20 minutes under the right conditions. Numerous gene modification techniques that have created countless enzymes and other commercial products have employed The facultative anaerobic bacteria E. coli, which typically contains more than 106 cells per gram of feces (2,3). Throughout the staining procedure, E. Coli turns pink as a result of absorbing the color of the counterstain, safranin. Penicillin cannot damage E. coli because the outer layer of the cell wall serves as a barrier against certain antibiotics (4). The bacterial group E. Coli is diverse and wide-ranging. Some forms of E. coli can make you sick, but most are harmless. While certain strains of E. coli can cause respiratory diseases including pneumonia and UTIs, others can cause diarrhea. In a mutualistic relationship, harmless strains of bacteria that are a component of the gut's natural microbiota can support their hosts by preventing harmful bacteria from colonizing the intestine and creating vitamin K2, which aids in blood coagulation (5).

PATHOGENICITYOF*ESCHERICHIACOLI*

Escherichia coli is a human pathogen. Along with commensal strains, E. coli also harbors dangerous strains that cause about 2 million deaths and a variety of human diseases each year. E. coli has six well-studied intestinal pathotypes: Shigella strains are subtypes of Shiga-producing E. Coli, including those that are enterotoxigenic (ETEC), enteropathogenic (EPEC), enteroaggregative (EAEC), diffusely adherent (DAEC), enteroinvasive (EIEC), and enterotoxigenic (ETEC). These strains are categorized according to their mechanisms of pathogenicity and virulence. leading to diarrhea and other digestive issues. Enterohaemorrhagic E. coli (EHEC) is one kind of STEC that can cause serious enteric infections such hemolytic uraemic syndrome and hemorrhagic colitis, which can lead to sudden renal failure and often death (5,6,7). Pathogenic E. coli strains are concerned in a number of waterborne outbreaks, and STEC and EPEC have been well recognized as the source of waterborne epidemics worldwide (8,9). Numerous traits of the organism and host-related variables influence how UTIs develop. In other words, according to the genetic makeup of the strain, the virulence of the UPEC is influenced by the host's genetic background as well as the functional and anatomical circumstances of the urinary tract (10).There are two ways that the microbes enter the urinary tract: the hematogenous route or the ascending route. The most popular path is the one that climbs. Here, the intestinal microbiota colonizes and moves up to the bladder and then the kidneys via the urethra. The haematogenous pathway of kidney infection is rare in healthy persons. Sometimes, in immunocompromised individuals with oral-sourced Candida fungemia or Staphylococcus aureus bacteremia, the renal parenchyma may be breached (1). Gram-negative UPEC is the most frequent causal agent of both complex and simple UTIs. Approximately 150 million persons globally have a UTI diagnosis each year (12). For instance, 90% of all simple UTIs, 65% of all severe UTIs, and up to 50% of all nosocomial UTIs are caused by community-acquired UTIs (13).

VIRULENCE FACTORS OF *ESCHERICHIA COLI*

In spite of strong host resistance, virulence factors allow the bacteria to infiltrate the host tissues and survive (14). the bacterial cell surface and those secreted and exported to the site of action are the two types of E. Coli virulence factors that have been identified as possibly important for colonization (15).

SURFACEVIRULENCEFACTORS

elucidate how the variety of sticky organelles, such as type 1 fimbriae, P fimbriae, S fimbriae, and F1C fimbriae, that encourage bacterial adhesion to the host tissue is one of the surface virulence factors of E. coli, seen figure (1) (16).

A) Type 1 fimbriae:

Bacteria's surface has filamentous projections called type 1 fimbriae, which are often protein-based. They can form biofilms and encourage targeted binding to receptors on the host's eukaryotic cells, including erythrocytes, urinary glycocalyx, and uroepithelial cells, on abiotic surfaces like plastic catheters. Type 1 fimbriae, the most prevalent adhesion factors in E. coli, are encoded by the fim gene cluster (17).

B) P Fimbriae:

The first common components of UPEC are P fimbriae, which are encoded by pap genes and are important in the pathophysiology of ascending UTIs and pyelonephritis in humans (18). Adhesion is their responsibility. A particular galactose disaccharide, present on the surface of uroepithelial cells in around 99 percent of the population, is bound by P fimbriae. The frequency of this host cell receptor's distribution contributes significantly to susceptibility and explains why some people get E. coli-caused UTIs repeatedly (19).

C) SFimbriaeandF1CFimbriae:

Both of these fimbriae types bind to kidney and lower urinary tract epithelial cells, which is how they are linked to UTIs (20). The E. coli strains that produce ascending UTIs are frequently linked to S fimbriae, which may aid in the spread of bacteria within host tissue (21).



Figure(1):Fimbriae mediatedadherenceofType1andType2,Pfimbriae of uropathogenic*E. coli* (22).

D) Capsule:

It is mostly covered and protected by a polysaccharide structure called a capsule. Complement and phagocytic engulfment are two host defensive mechanisms that the bacteria from the host immune system, the capsule, protects against (23). Capsular antigens (K antigen) are linked to upper urinary tract infections and aid in the pathophysiology of E. coli UTIs by encouraging bacterial populations in the host that resemble biofilms 24. By reducing complement and antibody binding to the bacterial surface, these capsules may increase bacterial pathogenicity (19).

E) Lipopolysaccharide:

Gram-negative bacteria have lipopolysaccharide (LPS) in their outer membrane. The three covalently bound components of LPS are an interior disaccharide with several fatty acids called lipid A, which is what causes the toxicity of Gram-negative bacteria (endotoxin), an outer carbohydrate chain of 1–50 oligosaccharide units called the O antigen, and a core oligosaccharide (25).

F) Flagella:

An organelle that is in charge of bacterial movement allows several harmful strains of Escherichia coli to interact with epithelial cells (26). Some studies suggest that E. Coli flagella may be crucial in allowing the bacteria to rise from the bladder and cause kidney infections in people. Seventy to ninety percent of all UTIs are caused by flagellated UPEC, and their pathogenesis involves bacterial interaction with the surface of the urinary tract's epithelial cells (27). Flagella have been proposed to increase bacterial pathogenicity by providing a selection advantage in the struggle for resources in the urine and promoting bacterial dispersal to the upper urinary tract (28).

SECRETEDVIRULENCEFACTORS

A) Toxins:

Numerous strains of E. coli release toxins that cause damage to the host's tissues or impair the host's immune system, therefore mediating infection (29). About 30–50% of UPEC isolates encode the pore-forming toxin α-hemolysin (HlyA), whose expression has been demonstrated to raise the clinical severity of UTIs (30). Since E. coli's alpha hemolysin also

lyses lymphocytes and its beta hemolysin prevents phagocytosis, hemolysin's function is not restricted to red blood cells (19). Its significance as invasive strains may be indicated by the increased frequency of hemolysin-producing strains isolated from urine (30).

B) Protease enzyme:

Proteases are thought to be significant virulence factors in infections that increase the invasiveness of organisms that harm host tissue and obstruct the host's defenses against microorganisms. The primary enzymes generated by microorganisms are proteases (31). The best microbial proteases for biotechnological processes are those with desired properties (32). According to Iqbal et al. (2013), proteases are well-known virulence agents that help numerous infections evade the immune system and survive(33).

REFERENCE

[1]. Shulman, S. T., Friedmann, H. C., & Sims, R. H. (2007). Theodor Escherich: the first pediatric infectious diseases physician?. Clinical infectious diseases, 45(8), 1025-1029.

[2]. Jang, J., Hur, H. G., Sadowsky, M. J., Byappanahalli, M. N., Yan, T.,& Ishii, S. (2017). Environmental *Escherichia coli*: ecology and public health implications—a review. Journal of applied microbiology, 123(3),570-581.

[3]. Tenaillon, O., Barrick, J. E., Ribeck, N., Deatherage, D. E.,Blanchard, J. L., Dasgupta, A., &Lenski, R. E. (2016). Tempo and mode of genome evolution in a 50,000-generation experiment. *Nature*, *536*(7615), 165-170.

[4]. Chikada, T., Kanai, T., Hayashi, M., Kasai, T., Oshima, T., &Shiomi, D. (2021). Direct observation of conversion from walled cells to walldeficient L-form and vice versa in *Escherichia coli* indicates the essentiality of the outer membrane for proliferation of L-form cells. Frontiers in microbiology, 12, 537.

[5]. Kaper, J.B., Nataro, J.P. and Mobley, H.L.T. (2004). Pathogenic *Escherichia coli.* Nat Rev Microbiol 2, 123–140.

[6]. Farrokh, C., Jordan, K., Auvray, F., Glass, K., Oppegaard, H.,Raynaud, S., & Cerf, O. (2013). Review of Shiga-toxin-producing *Escherichia coli* (STEC) and their significance in dairy production. International journal of food microbiology, 162(2), 190-212.

[7]. Sarowska, J., Futoma-Koloch, B., Jama-Kmiecik, A., Frej-Madrzak,M., Ksiazczyk, M., Bugla-Ploskonska, G., &Choroszy-Krol, I. (2019).Virulence factors, prevalence and potential transmission of extraintestinalpathogenic Escherichia coli isolated from different sources: recent reports. Gut pathogens, 11(1), 1-16.

[8]. Chandran, A. &Mazumder, A. (2015). Pathogenic potential, genetic diversity and population structure of *Escherichia coli* strains isolated from a forest-dominated watershed in British Columbia, Canada. Appl EnvironMicrobiol 81, 1788–1798.

[9]. Baliere, C., Rince, A., Blanco, J., Dahbi, G., Harel, J., Vogeleer, P.,Giard, J.-C., Mariani-Kurkdjian, P. (2015). Prevalence and characterization of Shiga toxin-producing and enteropathogenic*Escherichia coli* in shellfishharvesting areas and their watersheds. Front Microbiol 6, 1356.

[10]. Wang, O., McAllister, T.A., Plastow, G. (2017). Host mechanisms involved in cattle *Escherichia coli* O157 shedding: a fundamental understanding for reducing foodborne pathogen in food animal production. Sci Rep 7, 7630.

[11]. Robino, L., Scavone, P., Araujo, L., Algorta, G., Zunino, P., Pírez, M.C., &Vignoli, R. (2014). Intracellular bacteria in the pathogenesis of *Escherichia coli* urinary tract infection in children. Clinical Infectious Diseases, 59(11), e158-e164.

[12]. Stamm, W. E., &Norrby, S. R. (2001). Urinary tract infections: disease panorama and challenges. The Journal of infectious diseases, 183(Supplement_1), S1-S4.

[13]. Flores-Mireles, A. L., Walker, J. N., Caparon, M., &Hultgren, S. J.(2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature reviews microbiology, 13(5), 269-284.

[14]. Wiles, T. J., Kulesus, R. R., &Mulvey, M. A. (2008). Origins and virulence mechanisms of uropathogenic*Escherichia coli*. Experimental and molecular pathology, 8*5*(1), 11-19.

[15]. Bien, J., Sokolova, O., &Bozko, P. (2011). Characterization of virulence factors of *staphylococcus aureus*: Novel function of known virulence factors that are implicated in activation of airway epithelial proinflammatory response. Journal of pathogens, 2011, 601905.

[16]. Kudinha, T., Kong, F., Johnson, J. R., Andrew, S. D., Anderson, P., &Gilbert, G. L. (2012). Multiplex PCR-based reverse line blot assay forsimultaneous detection of 22 virulence genes in uropathogenic*Escherichia coli*. Applied and environmental microbiology, *78*(4), 1198-1202.

[17]. Aleksandrowicz, A., Khan, M. M., Sidorczuk, K., Noszka, M., &Kolenda, R. (2021). Whatever makes them stick–Adhesins of avian pathogenic *Escherichia coli*. Veterinary Microbiology, 257, 109095.

[18]. Jadhav, S., Hussain, A., Devi, S., Kumar, A., Parveen, S., Gandham, N., & Ahmed, N. (2011). Virulence characteristics and genetic affinities of multiple drug resistant uropathogenic*Escherichia coli* from a semi urban locality in India. PloS one, 6(3), e18063.

[19]. Todar, K. (2007). Pathogenic *E. coli*. textbook of bacteriology. University of Wisconsin Madison Department of Bacteriology, England.

[20]. Pobiega, M., Wojkowska-Mach, J., Chmielarczyk, A., Romaniszyn,D., Adamski, P., Heczko, P. B., &Grodzicki, T. (2013). Molecular characterization and drug resistance of *Escherichia coli* strains isolated from urine from long-term care facility residents in Cracow, Poland. Medical science monitor: international medical journal ofexperimental and clinical research, 19, 317.

[21]. Mulvey, M. A. (2002). Adhesion and entry of uropathogenic*Escherichia coli.* Cellular microbiology, 4(5), 257-271.

[22]. Govindarajan, D. K., &Kandaswamy, K. (2022). Virulence factors of uropathogens and their role in host pathogen interactions. The Cell Surface, 8, 100075.

[23]. Miajlovic, H., & Smith, S. G. (2014). Bacterial self-defence: how *Escherichia coli* evades serum killing. FEMS microbiology letters, 354(1), 1-9.

[24]. Ulett, G. C., Totsika, M., Schaale, K., Carey, A. J., Sweet, M. J., &Schembri, M. A. (2013). Uropathogenic*Escherichia coli* virulence and innate immune responses during urinary tract infection. Current opinion in microbiology, 16(1), 100-107.

[25]. Valvano, M. A. (2022). Remodelling of the Gram-negative bacterial Kdo2-lipid A and its functional implications. Microbiology, 168(4),001159.

[26]. Berg, H. C. (2003). The rotary motor of bacterial flagella. Annual review of biochemistry, 72(1), 19-54.

[27]. Schwan, W. R. (2008). Flagella allow uropathogenic*Escherichia coli* ascension into murine kidneys. International Journal of Medical Microbiology, 298(5-6), 441-447.

[28]. Lane, M. C., Alteri, C. J., Smith, S. N., & Mobley, H. L. (2007).Expression of flagella is coincident with uropathogenic*Escherichia coli* ascension to the upper urinary tract. Proceedings of the National Academyof Sciences, 104(42), 16669-16674.

[29]. Dobrindt, U., & Hacker, J. (2010). Uropathogens and virulence factors. Urogenital infections, 4-22.

[30]. Enrico, E. M. (2019). Defining the Interplay Between Bacterial Pore-Forming Toxins and Host Proteases. PhD-thesis Submitted College of Pathology, Utah University.

[31]. Ramírez-Larrota, J. S., &Eckhard, U. (2022). An Introduction to bacterial biofilms and their proteases, and their roles in host infection and immune evasion. Biomolecules, 12(2), 306.

[32]. Pant, G., Prakash, A., Pavani, J. V. P., Bera, S., Deviram, G. V. N. S.,Kumar, A., &Prasuna, R. G. (2015). Production, optimization and partial purification of protease from Bacillus subtilis. Journal of Taibah University for Science, 9(1), 50-55.

[33]. Iqbal, J., Rajani, M., Siddiqui, R., & Khan, N. A. (2013). Neuropathogenic Escherichia coli K1 does not exhibit proteolytic activities to exert its pathogenicity. Journal of Negative Results in BioMedicine, 12(1), 1-5.